Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
James Calderwood
Observed names:
Calderwood J,
J Calderwood
Observed institutions:
University of Dundee,
University of Oxford,
Medical Research Council
OpenAlex ID:
A5060718878
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021
·
Eugenia Abaleke
, Mustafa Abbas
, et al.
·
The Lancet
·
533
PDF
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021
·
Obbina Abani
, Ali Abbas
, et al.
·
The Lancet
·
493
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2022
·
Obbina Abani
, Ali Abbas
, et al.
·
The Lancet
·
369
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022
·
Obbina Abani
, Ali Abbas
, et al.
·
The Lancet
·
324
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021
·
Obbina Abani
, Ali Abbas
, et al.
·
The Lancet
·
290
Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial
2017
·
Guy E Thwaites
, Matthew Scarborough
, et al.
·
The Lancet
·
199
PDF
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2023
·
Obbina Abani
, Ali Abbas
, et al.
·
The Lancet
·
129
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023
·
O Abani
, A Abbas
, et al.
·
The Lancet Diabetes & Endocrinology
·
41
PDF
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024
·
Saul N Faust
, Richard Haynes
, et al.
·
The Lancet Child & Adolescent Health
·
39
PDF
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025
·
O Abani
, A Abbas
, et al.
·
The Lancet Infectious Diseases
·
12
PDF
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)
2024
·
Nicholas I. Paton
, Nicholas I. Paton
, et al.
·
EClinicalMedicine
·
3
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025
·
O Abani
, A Abbas
, et al.
·
The Lancet Infectious Diseases
PDF
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)
·
Stohr W
, Arenas-Pinto A
, et al.
·
Newcastle University ePrints (Newcastle Univesity)
PDF
Show more works
View as search
Works count:
13
Citation count:
2,431
H-index:
10
I10-index:
10
Year
Topic
Type
